Intensity Therapeutics Inc (INTS)

08:06 AM

Intensity Therapeutics Inc. Stock Analysis and ForecastExceptional profit potential - Autocar Professional

08:06 AM

01:45 AM

What analysts say about Intensity Therapeutics Inc. stockExponential return rates - jammulinksnews.com

01:45 AM

Jul 22, 2025

What drives Intensity Therapeutics Inc. stock priceExtraordinary market timing - Autocar Professional

Jul 22, 2025

Jul 22, 2025

Is Intensity Therapeutics Inc. a good long term investmentSky-high profits - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

How Intensity Therapeutics Inc. stock performs during market volatilityFree Membership Group - Newser

Jul 22, 2025

Jul 22, 2025

What makes Intensity Therapeutics Inc. stock price move sharplyFree Real-Time Market Predictions - Newser

Jul 22, 2025

Jul 21, 2025

The Business Case For Buying Intensity Therapeutics Inc (NASDAQ: INTS) Stock Now - Stocksregister

Jul 21, 2025

Jul 19, 2025

SBXD.U Stock Analysis and ForecastFree Investment Case Studies - Jammu Links News

Jul 19, 2025

Jul 18, 2025

Is EUDA a good long term investmentFree Investment Community - Jammu Links News

Jul 18, 2025

Jul 18, 2025

What drives World Kinect Corporation stock priceRapid portfolio appreciation - Jammu Links News

Jul 18, 2025

Jul 18, 2025

Intensity Therapeutics shareholders elect director and approve auditor at annual meeting - Investing.com

Jul 18, 2025

Jul 18, 2025

Intensity Therapeutics Holds Annual Stockholders’ Meeting - TipRanks

Jul 18, 2025

Jul 18, 2025

Is AFJKU a good long term investmentDynamic investment growth - Jammu Links News

Jul 18, 2025

Jul 17, 2025

why afloki(angryfloki) will explodeFree Access to Community - Newser

Jul 17, 2025

Jul 15, 2025

How LGCL stock performs during market volatilityCapital Efficient Investment Tips - Newser

Jul 15, 2025

Jul 15, 2025

Why BNAIW stock attracts strong analyst attentionFree Investment Community - Newser

Jul 15, 2025

Jul 15, 2025

How CAMP stock performs during market volatilityFree Smart Money Stock Analysis - Newser

Jul 15, 2025

Jul 15, 2025

What makes AACT.WS stock price move sharplyFree Long-Term Wealth Growth Plan - Newser

Jul 15, 2025

Jul 15, 2025

Why Mandatory Common Exchange Trust Preferred Security stock attracts strong analyst attention2x Return Forecast - Newser

Jul 15, 2025

Jul 15, 2025

Why Intensity Therapeutics Inc. stock attracts strong analyst attentionDaily Price Surge List - Newser

Jul 15, 2025

Jul 15, 2025

What makes Capricor Therapeutics Inc. stock price move sharplyDaily Stock Radar - Newser

Jul 15, 2025

Jul 15, 2025

Why Herc Holdings Inc. stock attracts strong analyst attentionFree Real-Time Market Predictions - Newser

Jul 15, 2025

Jul 15, 2025

How Apple Hospitality REIT Inc. stock performs during market volatilityFree Group Entry - Newser

Jul 15, 2025

Jul 15, 2025

Why REXR.PRC stock attracts strong analyst attentionLong Term Safe Yield Focus - Newser

Jul 15, 2025

Jul 15, 2025

How Ichor Holdings Ltd. stock performs during market volatilityHigh Accuracy Alerts - Newser

Jul 15, 2025

Jul 15, 2025

How LANDO stock performs during market volatilityTop Growth Low Risk Stocks - Newser

Jul 15, 2025

Jul 15, 2025

What makes flyExclusive Inc. Equity Warrant stock price move sharplySafe and Smart Investment Picks - Newser

Jul 15, 2025

Jul 14, 2025

INTS Stock: Exploring Intensity Therapeutics Inc’s Growth - investchronicle.com

Jul 14, 2025

Jul 14, 2025

OP’s Market Quandary: Decoding the Ups and Downs of 2025 - investchronicle.com

Jul 14, 2025

Jul 08, 2025

Intensity Therapeutics Inc’s Shares Reel: -85.34% Quarterly Revenue Decline Amid 7.38M Market Cap - investchronicle.com

Jul 08, 2025

Jul 04, 2025

Intensity Therapeutics Announces $2.3 Million Public Offering of Common Stock - Global Legal Chronicle

Jul 04, 2025

Jun 30, 2025

Oncology Innovation Just Hit a Turning Point — Here’s What to Watch - The Malaysian Reserve

Jun 30, 2025

Jun 30, 2025

Oncology Innovation Just Hit a Turning Point -- Here's What to Watch - The Globe and Mail

Jun 30, 2025

Jun 30, 2025

Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST) - Nasdaq

Jun 30, 2025

Jun 28, 2025

INTS SEC FilingsINTENSITY THERAPEUTICS INC 10-K, 10-Q, 8-K Forms - Stock Titan

Jun 28, 2025